Physicochemical Properties
| Molecular Formula | C20H20INO |
| Molecular Weight | 417.28 |
| Exact Mass | 692.303 |
| CAS # | 1206880-66-1 |
| PubChem CID | 44627267 |
| Appearance | Off-white to pink solid powder |
| LogP | 8.12 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 12 |
| Heavy Atom Count | 50 |
| Complexity | 1150 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | CC(=O)N1[C@@H](CC2=CC=CC=C21)COC3=CC4=C(C=C3)N(C(=C4SC(C)(C)C)CC(C)(C)C(=O)O)CC5=CC=C(C=C5)C6=NC=C(C=N6)OC |
| InChi Key | VYXWHVDEWWHDLH-LJAQVGFWSA-N |
| InChi Code | InChI=1S/C40H44N4O5S/c1-25(45)44-29(18-28-10-8-9-11-33(28)44)24-49-30-16-17-34-32(19-30)36(50-39(2,3)4)35(20-40(5,6)38(46)47)43(34)23-26-12-14-27(15-13-26)37-41-21-31(48-7)22-42-37/h8-17,19,21-22,29H,18,20,23-24H2,1-7H3,(H,46,47)/t29-/m0/s1 |
| Chemical Name | 1-Pentyl-3-(2-iodobenzoyl)indole |
| Synonyms | AM-679 AM679AM 679 SCHEMBL503239 65KJ8P7M9DUNII-65KJ8P7M9D CHEMBL595092 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | In an in vitro human FLAP membrane binding experiment, AM679 has an IC50 of 2 nM, indicating that it is a strong and selective FLAP inhibitor. The IC50 is 55 nM for both human blood and isolated ionophore-challenged mice as an inhibitor of LTB4 production. 154 nanometers [1]. With IC50 values of 2.2 nM/0.6 nM/154 nM for FLAP binding/hLA/hWB, respectively, AM679 is a strong and selective FLAP inhibitor[2]. |
| ln Vivo | In mouse bronchoalveolar lavage challenge models and human blood, AM679 exhibits strong inhibitory effects on leukotrienes [2]. |
| References |
[1]. A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye. Clinical and Vaccine Immunology (2009), 16(11), 1654-1659. [2]. 5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)-A potent FLAP inhib. |
Solubility Data
| Solubility (In Vitro) | DMSO : ≥ 100 mg/mL (~144.33 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.75 mg/mL (3.97 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (3.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3965 mL | 11.9824 mL | 23.9647 mL | |
| 5 mM | 0.4793 mL | 2.3965 mL | 4.7929 mL | |
| 10 mM | 0.2396 mL | 1.1982 mL | 2.3965 mL |